Logo

SIMA

SIM Acquisition Corp. I

SIMA

SIM Acquisition Corp. I • NASDAQ
$10.55 ▼ -0.24% (-0.03)
Market Cap $323.53 M
52w High $10.64
52w Low $10.00
Dividend Yield 0%
P/E 0
Volume 345
Outstanding Shares 30.67M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $258.011K ▲ $2.252M ▼ 0% $0.07 ▼ $0 ▼
Q2-2025 $0 $181.535K ▼ $2.298M ▲ 0% $0.075 ▲ $2.298M ▲
Q1-2025 $0 $241.472K ▼ $2.223M ▼ 0% $0.072 ▼ $-241K ▼
Q4-2024 $0 $264.21K ▼ $2.431M ▲ 0% $0.079 ▼ $2.431M ▲
Q3-2024 $0 $270.193K $2.357M 0% $0.08 $-270K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $169.145K ▼ $243.11M ▲ $10.95M $-10.559M ▼
Q2-2025 $346.169K ▼ $240.822M ▲ $10.95M $225.344M ▼
Q1-2025 $238.299M ▲ $238.557M ▲ $10.95M ▼ $227.567M ▲
Q4-2024 $697.085K ▼ $236.327M ▲ $10.983M ▲ $225.344M ▲
Q3-2024 $860.086K $233.873M $10.96M $222.913M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $4.473M ▲ $-177.024K ▼ $0 $0 $-177.024K ▼ $-177.024K ▼
Q2-2025 $2.298M ▲ $-165.528K ▲ $0 $0 $-165.528K ▲ $-165.528K ▲
Q1-2025 $2.223M ▲ $-185.388K ▲ $0 ▼ $0 ▲ $-185.388K ▼ $-185.388K ▲
Q4-2024 $-2.591M ▼ $-240.524K ▲ $293.307K ▲ $-230.963M ▼ $0 ▼ $-240.52K ▲
Q3-2024 $2.357M $-500.186K $0 $231.341M $840.834K $-500.19K

Five-Year Company Overview

Income Statement

Income Statement SIMA’s income statement is essentially a blank slate, which is typical for a newly formed SPAC. It has no real revenue and no operating business yet; any reported profit mainly reflects accounting items like interest on cash and the way SPACs are structured, not an underlying company performance. In practical terms, there is nothing here to analyze in the usual “sales and margins” sense until a merger target is chosen and combined with SIMA.

Balance Sheet

Balance Sheet The balance sheet is very light and clean: mostly equity capital with no meaningful debt and only modest assets showing at this stage. Economically, the core asset is the cash raised in the IPO and held in trust, even if that does not fully show up in the simplified figures provided. This structure limits financial risk today, but also means almost all of the company’s value depends on the future acquisition and how that acquired business looks financially.

Cash Flow

Cash Flow Cash flows today are minimal and mostly mechanical. There is effectively no cash generated from operations, no investment in long‑term assets, and activity is largely restricted to handling IPO proceeds and routine corporate costs. Real cash flow dynamics—both the ability to generate cash and the need to spend it—will only become visible after SIMA completes a business combination with an operating company.

Competitive Edge

Competitive Edge As a SPAC, SIMA’s competitive position is not about products or market share; it is about its ability to win attractive deals in a crowded environment. It competes with other SPACs, private equity funds, and strategic buyers to convince a strong private healthcare company to merge with it. Its edge comes from a leadership team with deep experience in intellectual property, healthcare, and capital markets, which can appeal to targets looking for smart partners who understand complex technology and regulation.

Innovation and R&D

Innovation and R&D SIMA itself does not conduct research and development, nor does it create new products. Its “innovation” lies in the know‑how of its team, especially around patents, healthcare innovation, and structuring deals. The real R&D story will only emerge once it selects a healthcare target—likely a business with meaningful intellectual property, medical technologies, or clinical assets—so future innovation depends entirely on that eventual choice.

Summary

SIMA is best viewed as a pool of capital attached to a specialized deal‑making team rather than a traditional operating company. Current financial statements tell very little about long‑term prospects; they mainly confirm a clean, low‑debt structure with no operating activity yet. The upside potential and the main risks both sit in the future: finding, evaluating, and successfully merging with a suitable healthcare company before its deadline. Until that deal is announced and detailed financials of the target are available, SIMA remains a high‑uncertainty, early‑stage vehicle whose value rests on management’s ability to source and execute a strong transaction.